Keyphrases
Severe Asthma
36%
Asthma
36%
Oral Corticosteroids
28%
Omalizumab
28%
Asthma Patients
22%
Dupilumab
20%
Mepolizumab
18%
Spain
15%
Allergic Asthma
14%
Moderate-to-severe Asthma
14%
Severe Eosinophilic Asthma
14%
Forced Expiratory Volume in 1 Second (FEV1)
13%
Therapeutic Approaches
12%
Mild Asthma
11%
Asthma Control
11%
Legionnaires' Disease
11%
Allergy
10%
Corticosteroids
10%
Inhaled Corticosteroids
9%
Long-term Safety
9%
Arterial Blood Gas
9%
Chronic Cough
9%
Community-acquired Pneumonia
9%
Embryology
9%
Chronic Obstructive Pulmonary Disease
9%
Monoclonal Antibody
8%
Dyspnea
8%
Anti-IgE
8%
Cough
7%
Placebo
7%
Corticosteroid Dose
7%
Asthma Management
7%
Diagnostic Procedures
7%
Legionella
7%
Eosinophils
6%
Erythromycin
6%
Legionellosis
6%
Spirometry
6%
Chest X-ray
6%
Long-term Efficacy
6%
Immunoglobulin E
6%
Oral Steroids
6%
ICS-LABA
6%
Pulmonary Hypoplasia
6%
Redes
6%
Adulthood
6%
Catalonia
6%
Patient Management
5%
Asthma Treatment
5%
Obstructive Sleep Apnea-hypopnea Syndrome (OSAHS)
5%
Pharmacology, Toxicology and Pharmaceutical Science
Asthma
100%
Omalizumab
24%
Disease
23%
Immunoglobulin E
20%
Mepolizumab
18%
Dupilumab
17%
Legionnaire Disease
14%
Chronic Obstructive Lung Disease
12%
Allergic Asthma
11%
Chronic Cough
9%
Monoclonal Antibody
9%
Legionella
8%
Coughing
8%
Adverse Event
7%
Dyspnea
7%
Placebo
7%
Erythromycin
6%
Methotrexate
6%
Hypoxemia
6%
Receptor
6%
Infection
5%
Legionella pneumophila
5%
Biological Marker
5%
Community Acquired Pneumonia
5%
Medicine and Dentistry
Asthma
46%
Chronic Obstructive Pulmonary Disease
15%
Diseases
15%
Lung
14%
Diagnosis
13%
Eosinophilic
13%
Pontiac Fever
12%
Mepolizumab
12%
Severe Asthma
10%
Dyspnea
10%
Arterial Blood Gas
9%
Hypoxemia
7%
Outpatient
6%
Pulmonary Hypoplasia
6%
Chronic Cough
6%
Home Oxygen Therapy
6%
Infection
6%
Quality of Life
6%
Forced Expiratory Volume
6%
Eosinophil
5%
Oxygen Therapy
5%
Community-Acquired Pneumonia
5%
Patient Compliance
5%
Health Care Cost
5%
